Recovery of pDIKE2 plasmid for Hepatitis C vaccine using CIMmultus™ C4 HLD Advanced Composite Column cGMP

10Sep2014

pIDKE2 plasmid is the main component of the CIGB's candidate vaccine against Hepatitis C virus (HVC), which is being used in HCV chronically-infected individuals, currently in clinical trial phases 1 and 2. Read the application note to see how the downstream process of pIDKE2 plasmid was improved, using a CIMmultus™ C4 HLD 800 mL, to purify sufficient quantities of HCV for clinical trials.

Read the application note here.